In vitro cytotoxicity of the conjugate adriamycin with anti-sarcoma monoclonal antibody 19-24.
Monoclonal antibody (MoAb) 19-24, which recognizes a cell surface sarcoma-associated antigen p102, was linked via a biotin-avidin-biotin bridge to adriamycin (ADR). The molar ratios of ADR: total protein ranged from 2 to 7.5. Significant differences were not observed between the binding ability of the ADR-MoAb conjugate and of the unconjugated MoAb 19-24 to fresh sarcoma tissue membranes. The ADR-MoAb conjugate also retained the ability to compete with MoAb 19-24 for binding to sarcoma-associated antigen p102. In vitro cytotoxicity studies using human fibrosarcoma cells showed that the ADR-MoAb conjugate maintained 40% of the efficacy of free ADR. However, the conjugate was not cytotoxic to p102 antigen negative rat fibrosarcoma SP-24 cells. These data support the suggestion that MoAb-drug conjugates might be helpful in developing highly specific antisarcoma therapeutic agents.
Mohamed
G
G
Specialized Center for Cancer Research and Education, University of Illinois College of Medicine, Chicago 60612.
Kuzmanoff
K M
KM
Stastny
J J
JJ
Das Gupta
T K
TK
D000911:Antibodies, Monoclonal / Q000276:immunology*; D002470:Cell Survival / Q000187:drug effects; D004317:Doxorubicin / Q000494:pharmacology*; D005354:Fibrosarcoma / Q000276:immunology* / Q000628:therapy; D006801:Humans; D000922:Immunotoxins; D014407:Tumor Cells, Cultured / Q000187:drug effects
D000911:Antibodies, Monoclonal; D000922:Immunotoxins; D004317:Doxorubicin